These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Narayanaswamy A; Neog A; Baskaran M; George R; Lingam V; Desai C; Rajadhyaksha V Indian J Ophthalmol; 2007; 55(2):127-31. PubMed ID: 17322603 [TBL] [Abstract][Full Text] [Related]
10. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group. Diestelhorst M Graefes Arch Clin Exp Ophthalmol; 2000 May; 238(5):433-9. PubMed ID: 10901475 [TBL] [Abstract][Full Text] [Related]
11. Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure. Sheppard JD; Comstock TL; Cavet ME Adv Ther; 2016 Apr; 33(4):532-52. PubMed ID: 26984315 [TBL] [Abstract][Full Text] [Related]
12. EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study. Berlin MS; Rowe-Rendleman C; Ahmed I; Ross DT; Fujii A; Ouchi T; Quach C; Wood A; Ward CL Br J Ophthalmol; 2016 Jun; 100(6):843-7. PubMed ID: 26453641 [TBL] [Abstract][Full Text] [Related]
13. Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial. Oddone F; Rossetti L; Tanga L; Berardo F; Ferrazza M; Michelessi M; Roberti G; Manni G; Centofanti M PLoS One; 2015; 10(10):e0140601. PubMed ID: 26484767 [TBL] [Abstract][Full Text] [Related]
14. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)]. Ge J; Li X; Sun X; He X; Zhang H Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999 [TBL] [Abstract][Full Text] [Related]
15. Prevention of corticosteroid-induced intraocular pressure elevation using ISV-205. Stewart WC; Arch Ophthalmol; 2003 Nov; 121(11):1543-7. PubMed ID: 14609909 [TBL] [Abstract][Full Text] [Related]
16. The effects of unoprostone isopropyl 0.12% and timolol maleate 0.5% on diurnal intraocular pressure. Stewart WC; Stewart JA; Kapik BM J Glaucoma; 1998 Dec; 7(6):388-94. PubMed ID: 9871860 [TBL] [Abstract][Full Text] [Related]
17. Validity of the Monocular Trial of Intraocular Pressure-Lowering at Different Time Points in Patients Starting Topical Glaucoma Medication. King AJ; Rotchford AP JAMA Ophthalmol; 2016 Jul; 134(7):742-7. PubMed ID: 27148831 [TBL] [Abstract][Full Text] [Related]
18. Risk of ocular hypertension in children treated with systemic glucocorticoid. Krag S; Larsen D; Albertsen BK; Glerup M Acta Ophthalmol; 2021 Dec; 99(8):e1430-e1434. PubMed ID: 33629533 [TBL] [Abstract][Full Text] [Related]
19. Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study. Brandt JD; Sall K; DuBiner H; Benza R; Alster Y; Walker G; Semba CP; Ophthalmology; 2016 Aug; 123(8):1685-1694. PubMed ID: 27157843 [TBL] [Abstract][Full Text] [Related]
20. Effect of latanoprost on the diurnal variations in the intraocular and ocular perfusion pressure in normal tension glaucoma. Ishibashi S; Hirose N; Tawara A; Kubota T J Glaucoma; 2006 Oct; 15(5):354-7. PubMed ID: 16988595 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]